# Observational Study to Evaluate the Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients

> **NCT03470961** · PHASE4 · UNKNOWN · sponsor: **Tianjin First Central Hospital** · enrollment: 45 (estimated)

## Conditions studied

- CKD (Chronic Kidney Disease) Stage 5T
- Diabetes Mellitus
- Simultaneous Pancreas Kidney Transplantation

## Interventions

- **DRUG:** Anti-Tlymphocyte Globulins
- **DRUG:** Anti-Thymocyte Globulins

## Key facts

- **NCT ID:** NCT03470961
- **Lead sponsor:** Tianjin First Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-01
- **Primary completion:** 2021-03-01
- **Final completion:** 2021-03-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2018-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03470961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03470961, "Observational Study to Evaluate the Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03470961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*